Skip to content

Middle Meningeal Artery Embolization Minimizes Burdensome Recurrence Rates After Newly Diagnosed Chronic Subdural Hematoma Evacuation

Middle Meningeal Artery Embolization Minimizes Burdensome Recurrence Rates After Newly Diagnosed Chronic Subdural Hematoma Evacuation - MEMBRANE

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00020465
Enrollment
154
Registered
2021-11-18
Start date
2022-05-26
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I62.02

Interventions

Group 1: Embolization of the branches of the MMA using digital subtraction angiography Group 2: Treatment according to clinical routine

Sponsors

Klinik für Neurochirurgie BG Klinikum Unfallkrankenhaus Berlin gGmbH
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients who were operated on by one or more burr hole trepanations for a first manifestation of a cSDH (unihemispheric or bihemispherical) proven in computer tomography or magnetic resonance tomography 2. Age =18 years 3. Adequate compliance and capacity to consent 4. Declaration of consent for the operation and study participation by the patient

Exclusion criteria

Exclusion criteria: 1. Conservatively treated cSDH 2. Radiological detection of an acute or subacute subdural hematoma, subarachnoid hemorrhage, intracerebral hematoma, epidural hematoma 3. Surgical technique: craniotomy, craniectomy, bilateral burr hole trepanation 4. Angiography cannot be performed within 72 hours after surgery 5. Age <18 years 6. Supervisory relationship 7. Pregnancy 8. No declaration of consent 9. Lack of compliance 10. Homozygous factor XIII deficiency with RA <10%

Design outcomes

Primary

MeasureTime frame
Recurrence of cSDH after operative therapy within 3 months after inclusion.

Secondary

MeasureTime frame
1. Impairment through neurological deficits assessed by the modified Rankin scale (mRS) 3 months after inclusion 2. Number of recurrence-associated complications with within 3 months of inclusion 3. 2. Number of complications associated with interventional therapy within 3 months of inclusion

Countries

Germany

Contacts

Public ContactLeonie Gölz

Institut für Radiologie und Neuroradiologie BG Klinikum Unfallkrankenhaus Berlin gGmbH

Leonie.Goelz@ukb.de030-56813829

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 15, 2026